Pharma Mar , Presentaciones en el 100 Congreso de la AACR en Denver ( EEUU ) del 18 al 22 Abril 2009 . Miercoles 22 abril , Tres Presentaciones .

... y las Tres últimas para este Miercoles 22 ... y a esperar que desde la Empresa nos lo expliquen bastante mejor ... :



11. Antitumor activity of Irvalec (PM02734) against lung cancer xenografts .

Ensayo con el Pariente del Kahalalide - F ... el Irvalec con demostrada actividad en Mama , Colon , Pancreas , Pulmón y Prostata . Este ensayo justifica el proseguir ensayos combinatorios con Erlotinib en Pacientes con Cancer de Pulmón .

******************************************************

12. Combination of plitidepsin and rituximab is effective for treatment of rituximab resistant Non-Hodgkin's B-cell lymphoma .

Ensayo del Aplidin que junto con Rituximab en Pacientes Linfoma No Hodgkin-B podria ser Viable .

******************************************************

13. ZNF93 overexpression is associated with ET-743 (Trabectedin; Yondelis®) and PM00104 (Zalypsis®) resistance in human cancer cell lines .


Differential expressions of ZNF93 and ZNF43 genes were confirmed in both CS-1/ER and CS-1/PR resistant cell lines. Furthermore, ZNF93 was overexpressed in two ET-743 resistant Ewing sarcoma cell lines as well as in a cisplatin resistant ovarian cancer cell line, but was not overexpressed in paclitaxel resistant cell lines. ZNF93 knockdown by siRNA in CS-1/ER and CS-1/PR caused increased sensitivity for ET-743, PM00104, and cisplatin. In conclusion, this study demonstrates that zinc finger proteins, specifically ZNF93, are involved in the resistance of ET-743 and PM00104.

Pharma Mar , Presentaciones en el 100 Congreso de la AACR en Denver ( EEUU ) del 18 al 22 Abril 2009 . Martes 21 abril , 4 presentaciones .

... deciamos que serian 13 las presentaciones ... pero hay una 14 ... concretamente una más del Zalypsis y que sera presentada hoy :

8. Synergistic action of plitidepsin and gemcitabine against pancreatic cancer in vitro and in vivo .

Dos ensayos para observar las Synergias entre Gemcitabine y Aplidin en Cancer de Pancreas .
Resultados : Inhibición del Crecimiento Tumoral en animales .





***********************************************

9. Irvalec, a novel marine cyclic peptide, enhances the antiproliferative effects of other anticancer drugs in human cancer cell lines .

Ensayo dirijido a analizar la actividad Antiproliferativa del Irvalec junto a Platinos - Gemcitabine - Rapamicine - Lapatinib ...

************************************************

10. PM01183 is a novel compound that binds DNA and displays cytotoxic effect in vitro and in vivo in human cancer cell lines .


Ensayo con el Compuestp PM001183 cuyos resultados apoyan el Futuro desarrollo de este Compuesto como Agente contra el Cancer .


************************************************


La del Zalypsis . poster 4527 :


Efecto que Zalypsis ejerce sobre las Lineas Celulares Tumorales ... expresion P53 .

*******************************************

Para mañana quedaran las 3 restantes Presentaciones de Pharma Mar ... y habria que esperar el Comunicado .

Aplidin , Fase II Relapsed/Refractory Aggressive Non Hodgkin Lymphoma ... Leucemia .

Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma .
This study is currently recruiting participants.
Verified by PharmaMar, April 2009
First Received: April 17, 2009 No Changes Posted
Sponsored by: PharmaMar

Information provided by: PharmaMar
ClinicalTrials.gov Identifier: NCT00884286

Purpose
This is a multicenter study to assess the anti-tumour activity,to investigate the safety profile and to obtain additional pharmacokinetic information for Aplidin® given as 1-hour weekly IV infusion in patients with aggressive non-Hodgkin's Lymphoma.



Condition Intervention Phase
Leukemia
Lymphoma
Drug: Aplidin®
Phase II